Xpa A23g Polymorphism is Associated with the Elevated Response to Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer

Jifeng Feng,Xinchen Sun,Ning Sun,Shukui Qin,Fan Li,Hongyan Cheng,Baoan Chen,YuanDong Cao,Jun Ma,Lu Cheng,Zuhong Lu,Jiazhong Ji,Yingfeng Zhou
DOI: https://doi.org/10.1093/abbs/gmp027
2009-01-01
Abstract:DNA repair capacity (DRC) is correlated with sensitivity of cancer cells toward platinum-based chemotherapy. We hypothesize that genetic polymorphisms in DNA repair gene XPA (xeroderma pigmentosum group A) and XPG (xeroderma pigmentosum group G) (ERCC5, excision repair cross-complementation group 5), which result in inter-individual differences in DNA repair efficiency, may predict clinical response to platinum agents in advanced non-small cell lung cancer (NSCLC) patients. In this study, we find that the Aright curved arrow G change of XPA A23G polymorphism significantly increased response to platinum-based chemotherapy. Polymorphism in XPG His46His was associated with a decreased treatment response, but was not statistically significant.
What problem does this paper attempt to address?